Abstract
In recent years, biological and regenerative injection therapies have increasingly been introduced as adjuncts to surgical procedures in cosmetic and functional gynecology, with the intention of sup-porting postoperative tissue healing, improving scar quality, preserving biomechanical integrity, and enhancing functional outcomes. This growing clinical interest has largely been driven by theoreti-cal biological mechanisms and extrapolation from other surgical fields; however, the strength and consistency of scientific evidence supporting their combined use with surgery remain limited. This narrative review critically examines the theoretical rationale, clinical applicability, limitations, and ethical considerations of combining biological and regenerative injections with surgical interventions in female genital aesthetic and functional surgery, within the framework of evidence-based medicine. Available literature suggests that platelet-rich plasma and platelet-rich fibrin may exert supportive, modulatory effects on early wound healing, angiogenesis, and scar remodeling in carefully selected patients, but these effects are modest, highly variable, and strongly influenced by preparation methods, application protocols, patient characteristics, and surgical technique. Autologous fat grafting is primar-ily a volume-restorative strategy, with any proposed regenerative influence considered secondary and inconsistent across studies, while nanofat applications remain exploratory, supported mainly by small observational series and subjective outcome measures. Exosome- and growth factor-based injections represent biologically intriguing concepts; however, insufficient standardization, unclear regulatory status, and lack of robust clinical data currently preclude their routine clinical use, particularly in combination with surgery. Across the literature, substantial heterogeneity in study design, outcome assessment, and follow-up duration limits reproducibility and generalizability of reported benefits. Importantly, biological and regenerative injections should not be interpreted as substitutes for me-ticulous surgical technique nor as interventions capable of fundamentally altering surgical outcomes. Within current evidence constraints, these approaches may be considered selected adjuvant options in specific clinical contexts characterized by compromised tissue quality, elevated wound-healing risk, or clinically relevant scar-related symptoms, provided that indications are clearly defined and patient expectations are transparently managed. Given the ethical and regulatory implications associated with unvalidated biological products, indiscriminate or routine application is not justified. Well-designed, controlled clinical studies with standardized protocols and long-term follow-up are required to clarify safety, efficacy, and the true clinical value of these interventions.